TARA-002 goes from looking better than Inlexzo to seeming rather worse.

Median PFS appears to back earlier response rate promise.

But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?

Welireg, Padcev, and a surprise fillip for Flare.

A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.

Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.

But Tevimbra’s role looks shaky as adverse events loom.

The group will start a pivotal trial of samuraciclib following promising second-line results.

Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.

The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.